Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-5,page-paged-5,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.1,vc_responsive

CLIENT NEWS

 

 

  • dievini Hopp BioTech holding GmbH & Co.KG: German Federal Government invests 300 Million Euros in CureVac
    www.dievini.de
  • Adocia Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 80th Scientific Sessions – Virtual experience
    www.adocia.com
  • AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients
    www.aicuris.com
  • MagForce AG and Affiliated European Clinics Support World Brain Tumor Day and Sponsor Various Patient Events to Raise Awareness for One of the Deadliest Oncological Indications
    www.magforce.de
  • APEIRON Biologics closes oversubscribed financing round of EUR 17.5 million for the development of APN01 against COVID-19
    www.apeiron-biologics.com
  • CENTOGENE AG: Resumption of air traffic at Rostock-Laage airport: CENTOGENE AG tests airport employees for the SARS-CoV-2-virus
    www.centogene.com
  • France Biotech: HealthTech For Care and EIT Health Announce Partnership to Support the Acceleration of European HealthTech Companies
    www.france-biotech.fr
  • faCellitate announces the launch of its first product BIOFLOAT™ for improved 3D cell culture
    www.facellitate.com
  • Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study
    www.atriva-therapeutics.com
  • Abivax announces German regulatory approval of ABX464 Covid-19 Phase 2b/3 COVID-19 clinical trial
    www.abivax.com